This site
is mobile
responsive


MIDA confident of drawing high quality investments this year

MIDA confident of drawing high quality investments this year

Its CEO,
Datuk Azman Mahmud, said Mida was confident of maintaining the momentum in
investments flowing into Malaysia in 2016 as the country’s fundamentals were
strong.

“Today
more people are confident (of investing) in Malaysia. There are no signs
showing investments are in downward trend.

“We can
maintain the momentum in investments coming into Malaysia this year,” he said.
He told a press conference this after attending the official opening ceremony
of Oncogen Pharma (M) Sdn Bhd’s Research and Development (R and D) Centre at
Glenmarie, near here.

Azman was
commenting on Mida’s overall investment outlook this year considering
Malaysia’s competitiveness as a location of choice for high-tech investment in
the region.

Mida had
approved some RM153.2bil of investments in the manufacturing sector for the
first nine months of last year and RM235.9bil for the whole of 2014. The 2015
full year figures will be announced on Feb 29.

Azman
said many investment deals were in the pipeline and as such, there were no
signs that indicated that investors were pulling out from their planned
investments in Malaysia.

Meanwhile,
Oncogen Pharma CEO, Junaid Waheed, said the company’s R and D centre was the
first Oncology Active Pharmaceutical Ingredients (API) research centre in Asean
that complied with the United States Food and Drug Administration (US FDA)
standards.

He said the centre would be a path-breaking
beginning in the company’s vision and commitment to supply high-quality
oncology products that complied with all the stringent international regulatory
requirements at affordable prices to majority of cancer patients. “These
products will be researched, developed and patented in Malaysia, and will then
be supplied to all over the world including the US and European markets,” he
said.

Source : Star Biz 

15 January 2016
TwitterLinkedInFacebookWhatsApp
wpChatIcon
X